Receptos Sets Estimated IPO Pricing Range

San Diego-based biopharmaceuticals developer Receptos has set the initial, estimated pricing range for its IPO, saying in a filing Thursday that it now expects its IPO pricing to be between $14.00 and $16.00 a share. THe firm, which has applied to list on the NASDAQ Global Market as RCPT, also said it will offer up 4,700,000 shares of its common stock in the IPO. Receptos is venture backed by ARCH Venture Partners, Flagship Ventures, Lilly Ventures Fund, Polaris Ventures, and Venrock Associates.